They Called It Impossible for 40 Years — Here's Why I'm Both Thrilled and Furious

The most pressing near-term milestone is Revolution Medicines' submission of a New Drug Application to the FDA for daraxonrasib. The drug already holds Breakthrough Therapy designation, Orphan Drug designation, and a Commissioner's National Priority Voucher — a combination of regulatory advantages that can substantially compress the standard review timeline. I expect the NDA to be filed in the second half of 2026, with Priority Review designation following, and a realistic pathway to formal FDA approval in the first half of 2027. The FDA's 48-hour turnaround on the expanded access application in late April 2026 — from filing on the 28th to approval on the 30th — signals that the agency is moving with the clinical urgency this disease demands. Formal approval is what converts the current expanded-access pathway into standard insurance coverage for the estimated 18,000 Americans diagnosed annually with second-line metastatic pancreatic adenocarcinoma, and the Commissioner's National Priority Voucher makes that 2027 timeline substantially more achievable than standard procedures would allow.

The drug pricing negotiation dynamics represent the most significant near-term headwind to commercial momentum. The Stifel-estimated monthly price of $30,547–$37,318 is nearly double the monthly cost of sotorasib, and at that level, daraxonrasib will almost certainly attract Medicare price negotiation pressure under the Inflation Reduction Act's strengthened drug pricing provisions. Revolution Medicines will argue that the breadth of mutation coverage and the magnitude of survival benefit justify the premium, and from a health economics standpoint, a drug producing HR 0.40 in second-line pancreatic cancer has a defensible value proposition in the American market. But the political environment around pharmaceutical pricing has shifted considerably, and large private insurers are increasingly deploying prior authorization requirements and step-therapy mandates as de facto price controls. I expect the effective realized price per patient in the U.S. to settle meaningfully below the list price over time — though the trajectory of that convergence will depend heavily on how aggressively CMS exercises its new negotiation authority.

The RASolute 303 Phase 3 trial is the second major near-term signal to monitor closely. The first patient was dosed in April 2026, with approximately 900 patients planned across daraxonrasib monotherapy and daraxonrasib combined with gemcitabine and nab-paclitaxel — the current first-line standard of care. I believe enrollment will proceed faster than typical for a pancreatic cancer indication. The second-line Phase 3 data was so compelling that patients and oncologists seeking trial access will drive aggressive participation at sites already running established RASolute 302 operational infrastructure. Full results from RASolute 303 will not arrive before 2028 at the earliest, but interim analyses and safety data presented at conferences along the way will shape clinical practice patterns and market expectations well before the primary endpoint readout. How quickly the trial completes enrollment will itself become a meaningful leading indicator.

Phase 1/2 combination therapy preliminary data has already produced numbers that make the first-line case look credible: an objective response rate of 58%, a disease control rate of 90%, a six-month progression-free survival rate of 84%, and a six-month overall survival rate of 90%. These are striking signals for a first-line pancreatic setting where the current standard of care (gemcitabine plus nab-paclitaxel) produces a median overall survival of approximately 8.5 months and a one-year survival rate under 35%. I want to be appropriately cautious here — this is early-phase, small-cohort data, and small Phase 1/2 cohorts in pancreatic cancer have disappointed in large randomized Phase 3 settings many times before. But the direction is consistent with what a drug of daraxonrasib's demonstrated second-line potency should theoretically be capable of in the first-line setting, and it provides scientific rationale for sustained optimism about RASolute 303.

Looking at the medium-term landscape from 2027 through 2028, the competitive dynamics around daraxonrasib will take meaningful shape. MRTX1133, the KRAS G12D-specific inhibitor now part of Bristol-Myers Squibb following the Mirati acquisition, is progressing through Phase 1/2 and could reach Phase 3 readiness by 2027. The clinical distinction matters: daraxonrasib's broad-spectrum approach covers G12D, G12V, and G12R simultaneously, while MRTX1133 targets G12D specifically — the single most common KRAS variant in pancreatic cancer at 40%. For G12D-dominant tumors, a selective inhibitor might achieve a cleaner pharmacological profile; for tumors with mixed KRAS variants, the broad-spectrum approach likely wins. I expect this differentiation to generate productive scientific competition rather than zero-sum displacement. More than 60 RAS-targeted drugs are in development globally, including SHP2 inhibitors, SOS1 inhibitors, and RAF inhibitors being explored specifically as combination partners to address known resistance mechanisms — and the 2027–2028 window will see the first meaningful Phase 2 readouts from many of these programs.

Resistance is, in my view, the single most important variable determining daraxonrasib's long-term impact — and the one most likely to complicate the current "game changer" framing. Research presented at AACR has already documented acquired resistance mechanisms in patients on daraxonrasib monotherapy: KRAS amplification in three patients, MAP2K1/2 mutations in five, and PI3K/MTOR pathway alterations in four. A 2026 paper published in Cell identified molecular glue complex disruption as a resistance mechanism that may not be specific to daraxonrasib but could apply to the entire class of RAS(ON) inhibitors — a broader structural concern for the field. By 2028, patients who began daraxonrasib in 2026 or 2027 will have longitudinal follow-up data revealing how the survival curve evolves beyond the current 13.2-month median. If the curve's tail is encouragingly long, it validates the current optimism. If resistance emerges broadly and drives the survival curve toward the chemotherapy arm at 18–24 months, the urgency of combination strategies increases substantially and the monotherapy's commercial ceiling compresses. The precedent of sotorasib — whose real-world durable benefit proved narrower than initial Phase 2 enthusiasm suggested — makes this a scenario to take seriously rather than dismiss.

Looking out to 2028 through 2031, the potentially transformational development for daraxonrasib is indication expansion beyond pancreatic cancer. KRAS mutations appear in roughly 25% of non-small cell lung cancers and 40–50% of colorectal cancers — two of the most common cancers globally — making these the most important potential expansion opportunities. Market analyst projections for daraxonrasib's peak annual revenue in pancreatic cancer alone run to $5–8.5 billion. Successful expansion into lung and colorectal settings could push peak revenue above $10 billion, placing daraxonrasib among the top-tier global pharmaceutical blockbusters. I believe indication expansion is the most likely long-term development pathway — but each new cancer type requires its own dedicated Phase 3 trial, and the tumor microenvironment, co-mutation landscape, and established treatment sequences in lung and colorectal cancer differ meaningfully from pancreatic cancer. The expansion is not automatic, and assuming smooth translation from the pancreatic Phase 3 success would be a significant analytical error.

The demographic backdrop for all of these projections is one of accelerating need. A 2026 Journal of Global Health analysis projects global pancreatic cancer incidence to increase 95.4% by 2050, reaching approximately 998,663 cases annually — driven by aging populations, rising obesity rates, and increasing type 2 diabetes prevalence worldwide. In the United States, pancreatic cancer is forecast to overtake colorectal cancer as the second leading cause of cancer death by 2030. This epidemiological tide is rising precisely as effective targeted therapies are becoming available for the first time. The structural irony is that incidence is growing fastest in low- and middle-income regions where a $37,000-per-month drug is not a pricing discussion but a categorical impossibility. Without deliberate policy intervention, the gap between what science can do and what reaches most patients will widen even as the science improves.

I believe structural policy solutions are becoming increasingly inevitable, though their timeline remains uncertain. The combination of rising incidence, dramatic survival benefit, and extreme pricing creates political and policy pressure that will be difficult to contain through the 2030s. Compulsory licensing — permitting generic manufacturers to produce a drug without the patent holder's consent in exchange for royalties — is explicitly authorized under the World Trade Organization's TRIPS Agreement for public health emergencies, and arguments for its application to daraxonrasib in high-burden, low-resource settings will eventually be made in multilateral forums. Tiered pricing agreements, where pharmaceutical companies offer substantially reduced prices in low- and middle-income countries in exchange for re-importation restrictions, represent a less confrontational middle path that some companies have adopted for HIV medications without compromising global profitability. I expect both mechanisms to become live regulatory and political debates before 2030, and their resolution will determine whether daraxonrasib's scientific achievement ultimately translates into meaningful global health impact or remains accessible only to a small fraction of the world's patients.

In the bull-case scenario, FDA approval arrives in the first half of 2027 with manageable pricing friction; RASolute 303 first-line results in 2028–2029 demonstrate a hazard ratio in the 0.45–0.50 range, confirming the second-line effect translates to the first-line setting; lung and colorectal indication programs reach Phase 3 enrollment by 2029–2030 and deliver preliminary results by 2031; and peak annual revenue exceeds $8.5 billion. The Commissioner's National Priority Voucher and Breakthrough Therapy designation make the FDA timeline plausible, the Phase 1/2 combination data (ORR 58%, six-month OS 90%) provides empirical foundation for first-line optimism, and a tiered pricing agreement by 2029 partially addresses the global equity gap. This scenario is supported by the extraordinary strength of the Phase 3 data — an HR of 0.40 with p=4.6×10⁻¹¹ rarely fails to generate downstream regulatory momentum.

In the base case, FDA approval comes in 2027; first-line RASolute 303 results arrive in 2029 with a solid but smaller effect size than second-line (HR around 0.52–0.58); indication expansions into lung and colorectal cancer proceed methodically but face meaningful competition from mutation-specific inhibitors; acquired resistance data shows that durable benefit concentrates in a biomarker-identifiable responder subpopulation; and peak annual revenue stabilizes in the $5–7 billion range. In the bear case, acquired resistance mechanisms emerge more broadly and rapidly than current data suggests, affecting the majority of second-line patients within 12–15 months, and the durable survival tail proves limited to a small subset. First-line RASolute 303 data disappoints with HR 0.65 or higher. Aggressive Medicare price negotiation compresses realized prices enough to dampen U.S. commercial uptake, and peak revenue falls below $3 billion. This is not the most likely outcome, but the sotorasib precedent makes it a scenario to hold with intellectual honesty rather than dismiss on the basis of Phase 3 enthusiasm alone.

Finally, let me be transparent about what could invalidate my forecast. My strongest concern is resistance, and that concern could resolve more favorably than I expect if combination therapy strategies — daraxonrasib plus SHP2 inhibitor, plus EGFR inhibitor, or plus immunotherapy — produce durable Phase 2 responses in 2027 that demonstrate effective management of the identified resistance pathways. Conversely, if political pressure on pharmaceutical pricing proves faster and stronger than I project — if the U.S. government or major European authorities negotiate or mandate prices toward $10,000–$15,000 per month — global access could improve more rapidly than my current estimates suggest. Whatever scenario plays out, one thing is fixed: daraxonrasib has made the "undruggable" druggable, and the scientific momentum that follows from that proof of concept will reshape oncology regardless of what happens to this particular molecule. If you or a loved one is living with pancreatic cancer, please work closely with your oncologist to explore eligibility for the expanded access program or the RASolute 303 trial. Treatment effects vary by individual, and all decisions must be guided by a physician who knows your full clinical picture.